Azitra, Inc.
AZTRHealthcare|Biotechnology|US
$0.73
+0.01 (+1.02%)
DCF Value
$2.87
Tangible Book / Share
$3.55
Cash / Share
$3.49
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06830863 A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity | EGFR Inhibitor-associated Rash | P1P2 | Recruiting | 32 | RCT, Double-blind | ATR04-484, Vehicle |
| NCT04731259 Study to Evaluate the Safety of ATR-04 | Epidermal Growth Factor, Papulopustular Rosacea | P1P2 | Withdrawn | — | RCT, Double-blind | ATR-04 |
| NCT06137157 Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome | Netherton Syndrome | P1 | Completed | 6 | Open-label | ATR12-351 |
| NCT03820076 Safety Study of AZT-04 for Cosmetic Use | Study of Three Doses of AZT-04 for Skin Appearance | N/A | Completed | 21 | RCT, Double-blind | — |